133 related articles for article (PubMed ID: 23406641)
1. [Fatal interstitial lung disease associated with erlotinib use].
Eshuis M; Ahsmann EJ; van Egmond NH
Ned Tijdschr Geneeskd; 2013; 157(7):A5519. PubMed ID: 23406641
[TBL] [Abstract][Full Text] [Related]
2. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
[TBL] [Abstract][Full Text] [Related]
3. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
[TBL] [Abstract][Full Text] [Related]
4. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
Chou CL; Ko HW; Wang CW; Yu CT; Kuo HP; Huang CD
Chang Gung Med J; 2010; 33(1):100-5. PubMed ID: 20184801
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
Tsubata Y; Hamada A; Sutani A; Isobe T
J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540
[TBL] [Abstract][Full Text] [Related]
7. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
ter Heine R; van den Bosch RT; Schaefer-Prokop CM; Lankheet NA; Beijnen JH; Staaks GH; van der Westerlaken MM; Malingré MM; van den Brand JJ
Lung Cancer; 2012 Mar; 75(3):391-7. PubMed ID: 22101147
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary toxicity associated with erlotinib.
Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
[TBL] [Abstract][Full Text] [Related]
10. High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
Fujita K; Hirose T; Kusumoto S; Sugiyama T; Shirai T; Nakashima M; Akiyama Y; Sasaki Y
Lung Cancer; 2014 Oct; 86(1):113-4. PubMed ID: 25123334
[No Abstract] [Full Text] [Related]
11. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
14. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
15. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
[TBL] [Abstract][Full Text] [Related]
17. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Stepanski EJ; Houts AC; Schwartzberg LS; Walker MS; Reyes CM; Blakely J
Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
Merimsky O; Cheng CK; Au JS; von Pawel J; Reck M
Oncol Rep; 2012 Aug; 28(2):721-7. PubMed ID: 22614912
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Bai H; Han B
Am J Clin Oncol; 2013 Apr; 36(2):110-5. PubMed ID: 22391431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
